Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

August 1, 2024

https://www.prnewswire.com/news-releases/blueprint-medicines-reports-second-quarter-2024-results-and-raises-ayvakitayvakyt-avapritinib-full-year-revenue-guidance-302211814.html

— Achieved $114.1 million in AYVAKIT net product revenues in the second quarter 2024 —

— Raising AYVAKIT net product revenue guidance to $435 million to $450 million for 2024 —

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.